127 related articles for article (PubMed ID: 37530515)
1. An Exploratory Pilot Study of Neuropsychological Performance in Two Huntington Disease Centers of Excellence Clinics.
Rossetti MA; Anderson KM; Hay KR; Del Bene VA; Celka AS; Piccolino A; Nelson Sheese AL; Huynh M; Zhu L; Claassen DO; Furr Stimming E; Considine CM
Arch Clin Neuropsychol; 2024 Jan; 39(1):24-34. PubMed ID: 37530515
[TBL] [Abstract][Full Text] [Related]
2. Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington's disease gene-expansion carriers.
Unmack Larsen I; Vinther-Jensen T; Gade A; Nielsen JE; Vogel A
J Int Neuropsychol Soc; 2015 Mar; 21(3):193-202. PubMed ID: 25850430
[TBL] [Abstract][Full Text] [Related]
3. Visual Object Perception in Premanifest and Early Manifest Huntington's Disease.
Coppen EM; Jacobs M; van der Zwaan KF; Middelkoop HAM; Roos RAC
Arch Clin Neuropsychol; 2019 Nov; 34(8):1320-1328. PubMed ID: 30796801
[TBL] [Abstract][Full Text] [Related]
4. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.
Hart EP; Dumas EM; Schoonderbeek A; Wolthuis SC; van Zwet EW; Roos RA
Mov Disord; 2014 Mar; 29(3):320-6. PubMed ID: 24500841
[TBL] [Abstract][Full Text] [Related]
5. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.
Stout JC; Queller S; Baker KN; Cowlishaw S; Sampaio C; Fitzer-Attas C; Borowsky B;
Mov Disord; 2014 Sep; 29(10):1281-8. PubMed ID: 25209258
[TBL] [Abstract][Full Text] [Related]
6. Factor Structure of the Repeatable Battery for the Assessment of Neuropsychological Status in Huntington's Disease.
Springate BA; Carvalho JO
Arch Clin Neuropsychol; 2022 Feb; 37(2):473-478. PubMed ID: 34331058
[TBL] [Abstract][Full Text] [Related]
7. Language disintegration in spontaneous speech in Huntington's disease: a more fine-grained analysis.
Tovar A; Garí Soler A; Ruiz-Idiago J; Mareca Viladrich C; Pomarol-Clotet E; Rosselló J; Hinzen W
J Commun Disord; 2020; 83():105970. PubMed ID: 32062158
[TBL] [Abstract][Full Text] [Related]
8. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease.
Vinther-Jensen T; Larsen IU; Hjermind LE; Budtz-Jørgensen E; Nielsen TT; Nørremølle A; Nielsen JE; Vogel A
Orphanet J Rare Dis; 2014 Jul; 9():114. PubMed ID: 25026978
[TBL] [Abstract][Full Text] [Related]
9. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
10. Time will tell: Decision making in premanifest and manifest Huntington's disease.
Heim B; Peball M; Saft C; von Hein SM; Ellmerer P; Piater JM; Seppi K; Djamshidian A
Brain Behav; 2020 Nov; 10(11):e01843. PubMed ID: 32978893
[TBL] [Abstract][Full Text] [Related]
11. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
[TBL] [Abstract][Full Text] [Related]
12. The Repeatable Battery for the Assessment of Neuropsychological Status, While Useful for Measuring Cognitive Changes in Manifest Huntington Disease, May Show Limited Utility in Premanifest Disease.
Mustafa AI; Corey-Bloom J; Beltran-Najera I; Snell C; Castleton J; Smith H; Gilbert PE
Cogn Behav Neurol; 2022 Sep; 35(3):198-203. PubMed ID: 35830248
[TBL] [Abstract][Full Text] [Related]
13. Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease.
Smith MM; Mills JA; Epping EA; Westervelt HJ; Paulsen JS;
Neuropsychology; 2012 Sep; 26(5):664-9. PubMed ID: 22846033
[TBL] [Abstract][Full Text] [Related]
14. Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease.
Julayanont P; Heilman KM; McFarland NR
Mov Disord; 2020 May; 35(5):781-788. PubMed ID: 31922295
[TBL] [Abstract][Full Text] [Related]
15. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.
Lemiere J; Decruyenaere M; Evers-Kiebooms G; Vandenbussche E; Dom R
J Neurol; 2004 Aug; 251(8):935-42. PubMed ID: 15316797
[TBL] [Abstract][Full Text] [Related]
16. [Huntington chorea. Clinical correlations and preliminary neuropsychological data].
Fragassi NA; Stanzione M; Angelini R; Di Maio L
Acta Neurol (Napoli); 1992; 14(4-6):530-6. PubMed ID: 1293994
[TBL] [Abstract][Full Text] [Related]
17. Severity of cognitive impairment in juvenile and late-onset Huntington disease.
Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J
Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and initial validation of 'HD-Mobile', a smartphone application for remote self-administration of performance-based cognitive measures in Huntington's disease.
McLaren B; Andrews SC; Glikmann-Johnston Y; Mercieca EC; Murray NWG; Loy C; Bellgrove MA; Stout JC
J Neurol; 2021 Feb; 268(2):590-601. PubMed ID: 32880724
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year.
Lemiere J; Decruyenaere M; Evers-Kiebooms G; Vandenbussche E; Dom R
Acta Neurol Scand; 2002 Sep; 106(3):131-41. PubMed ID: 12174172
[TBL] [Abstract][Full Text] [Related]
20. Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington's Disease.
Achenbach J; Matusch A; Elmenhorst D; Bauer A; Saft C
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
